BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernando A, Pattison J, Horsfield C, D’cruz D, Cook G, O’brien T. [ 18 F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. European Urology 2017;71:926-33. [DOI: 10.1016/j.eururo.2016.10.046] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Si M, Zhang K, Li J, He H, Yao Y, Han J, Qiao J. Idiopathic retroperitoneal fibrosis with endometrial cancer: a case report and literature review. BMC Womens Health 2022;22:399. [PMID: 36183056 DOI: 10.1186/s12905-022-01968-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Habib A. A rare presentation of acute kidney failure due to retroperitoneal fibrosis as a result of gastric linitis plastica: a case-based review. Journal of Kidney Care 2022;7:226-230. [DOI: 10.12968/jokc.2022.7.5.226] [Reference Citation Analysis]
3 Jamar F, Gormsen LC, Yildiz H, Slart RH, van der Geest KS, Gheysens O. The role of PET/CT in large vessel vasculitis and related disorders: diagnosis, extent evaluation and assessment of therapy response. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03465-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Dondi F, Albano D, Giubbini R, Bertagna F. PET in idiopathic retroperitoneal fibrosis. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00059-4] [Reference Citation Analysis]
5 Lee SJ, Eun JS, Kim MJ, Song YW, Kang YM. Association of retroperitoneal fibrosis with malignancy and its outcomes. Arthritis Res Ther 2021;23:249. [PMID: 34565447 DOI: 10.1186/s13075-021-02627-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mizushima I, Kawano M. Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges. Int J Nephrol Renovasc Dis 2021;14:279-89. [PMID: 34349543 DOI: 10.2147/IJNRD.S239160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Uddin M, Varley R, Napier-hemy R. Our experience in laparoscopic ureterolysis and omental wrapping as a definitive surgical management of ureteric obstruction related to retroperitoneal fibrosis. Journal of Clinical Urology. [DOI: 10.1177/20514158211022215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jolobe OMP. Immunoglobulin G4-related disease as the alternative diagnosis. QJM 2021;114:144. [PMID: 33159450 DOI: 10.1093/qjmed/hcaa303] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gao W, Xing T, Ou T. The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis. BMC Urol 2021;21:53. [PMID: 33827529 DOI: 10.1186/s12894-021-00815-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep 2021;23:18. [PMID: 33569638 DOI: 10.1007/s11926-020-00966-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
11 Sheth R, Malik D. Bilateral Hydronephrosis From Retroperitoneal Fibrosis. Cureus 2020;12:e12147. [PMID: 33489559 DOI: 10.7759/cureus.12147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant 2020:gfaa083. [PMID: 33005943 DOI: 10.1093/ndt/gfaa083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
13 Le Joncour A, Saadoun D, Cacoub P. La fibrose rétropéritonéale idiopathique. Rev Med Interne 2020;41:822-8. [PMID: 32727694 DOI: 10.1016/j.revmed.2020.06.013] [Reference Citation Analysis]
14 Peisen F, Thaiss WM, Ekert K, Horger M, Amend B, Bedke J, Nikolaou K, Kaufmann S. Retroperitoneal Fibrosis and its Differential Diagnoses: The Role of Radiological Imaging. Rofo 2020;192:929-36. [DOI: 10.1055/a-1181-9205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
15 Shakir MKM, Hoang TD, Johnson JT, Mai VQ. Supraphysiological doses of glucocorticoids induce remission in a patient with retroperitoneal fibrosis but no effect on the course of Hashimoto’s thyroiditis: a discordant mode of action. Modern Rheumatology Case Reports 2019;3:172-178. [DOI: 10.1080/24725625.2019.1622859] [Reference Citation Analysis]
16 Moreau A, Giraudet AL, Mognetti T, Kryza D. Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 2019;46:1758-9. [DOI: 10.1007/s00259-019-04352-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hanssen O, Lovinfosse P, Weekers L, Hustinx R, Jouret F. [18F-FDG positron emission tomography in non-oncological renal pathology: Current indications and perspectives]. Nephrol Ther 2019;15:430-8. [PMID: 30982747 DOI: 10.1016/j.nephro.2018.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, Dick F, van Herwaarden J, Karkos C, Koelemay M, Kölbel T, Loftus I, Mani K, Melissano G, Powell J, Szeberin Z, Esvs Guidelines Committee, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Kolh P, Lindholt JS, de Vega M, Vermassen F, Document reviewers, Björck M, Cheng S, Dalman R, Davidovic L, Donas K, Earnshaw J, Eckstein H, Golledge J, Haulon S, Mastracci T, Naylor R, Ricco J, Verhagen H. Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. European Journal of Vascular and Endovascular Surgery 2019;57:8-93. [DOI: 10.1016/j.ejvs.2018.09.020] [Cited by in Crossref: 1052] [Cited by in F6Publishing: 873] [Article Influence: 350.7] [Reference Citation Analysis]
19 Adnan S, Bouraoui A, Mehta S, Banerjee S, Jain S, Dasgupta B. Retroperitoneal fibrosis; a single-centre case experience with literature review. Rheumatol Adv Pract 2019;3:rky050. [PMID: 31431986 DOI: 10.1093/rap/rky050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Palmisano A, Maritati F, Vaglio A. Chronic Periaortitis: an Update. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0789-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
21 Kamper L, Dreger NM, Brandt AS, Pöppel T, Abanador-kamper N, Roth S, Haage P. Diffusion-weighted MRI and PET–CT in the follow up of chronic periaortitis. Int J Cardiovasc Imaging 2018;34:1779-85. [DOI: 10.1007/s10554-018-1395-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Accorsi Buttini E, Maritati F, Vaglio A. [ 18 F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis. European Urology 2018;73:145-6. [DOI: 10.1016/j.eururo.2017.09.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
23 Grozdic Milojevic IT, Milojevic B, Sobic-Saranovic DP, Artiko VM. Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review. Rheumatol Int 2018;38:179-87. [PMID: 28840309 DOI: 10.1007/s00296-017-3798-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
24 Wang Y, Guan Z, Gao D, Luo G, Li K, Zhao Y, Wang X, Zhang J, Jin J, Zhao Z, Yang C, Zhang J, Zhu J, Huang F. The value of 18F-FDG PET/CT in the distinction between retroperitoneal fibrosis and its malignant mimics. Semin Arthritis Rheum 2018;47:593-600. [PMID: 28958769 DOI: 10.1016/j.semarthrit.2017.07.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
25 Gu L, Wang Y, Zhang X. Re: Archie Fernando, James Pattison, Catherine Horsfield, David D’Cruz, Gary Cook, Tim O’Brien. [18F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. Eur Urol 2017;71:926–33. European Urology 2017;72:e43-e44. [DOI: 10.1016/j.eururo.2017.02.029] [Reference Citation Analysis]
26 Brandt AS, Dreger NM, Müller E, Kukuk S, Roth S. Neue (und alte) Aspekte der retroperitonealen Fibrose. Urologe 2017;56:887-94. [DOI: 10.1007/s00120-017-0428-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
27 O'brien T, Fernando A. Contemporary role of ureterolysis in retroperitoneal fibrosis: treatment of last resort or first intent? An analysis of 50 cases. BJU Int 2017;120:556-61. [DOI: 10.1111/bju.13915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
28 Fendler WP, Eiber M, Stief CG, Herrmann K. A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis? European Urology 2017;71:934-935. [DOI: 10.1016/j.eururo.2017.01.019] [Reference Citation Analysis]